BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24584876)

  • 1. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.
    Ruddy KJ; O'Neill A; Miller KD; Schneider BP; Baker E; Sparano JA; Dang C; Northfelt DW; Sledge GW; Partridge AH
    Breast Cancer Res Treat; 2014 Apr; 144(3):591-7. PubMed ID: 24584876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
    Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
    Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
    Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
    Swain SM; Land SR; Ritter MW; Costantino JP; Cecchini RS; Mamounas EP; Wolmark N; Ganz PA
    Breast Cancer Res Treat; 2009 Jan; 113(2):315-20. PubMed ID: 18302020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
    Ruddy KJ; Guo H; Barry W; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Hudis C; Krop IE; Burstein HJ; Winer EP; Partridge AH; Tolaney SM
    Breast Cancer Res Treat; 2015 Jun; 151(3):589-96. PubMed ID: 25981899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer.
    Turnbull AK; Patel S; Martinez-Perez C; Rigg A; Oikonomidou O
    Breast Cancer Res Treat; 2021 Feb; 186(1):237-245. PubMed ID: 33047206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
    Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
    Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
    Anderson RA; Kelsey TW; Perdrix A; Olympios N; Duhamel O; Lambertini M; Clatot F
    Breast Cancer Res Treat; 2022 Apr; 192(2):273-282. PubMed ID: 34997365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
    Ruddy KJ; Zheng Y; Tayob N; Hu J; Dang CT; Yardley DA; Isakoff SJ; Valero VV; Faggen MG; Mulvey TM; Bose R; Sella T; Weckstein DJ; Wolff AC; Reeder-Hayes KE; Rugo HS; Ramaswamy B; Zuckerman DS; Hart LL; Gadi VK; Constantine M; Cheng KL; Briccetti FM; Schneider BP; Merrill Garrett A; Kelly Marcom P; Albain KS; DeFusco PA; Tung NM; Ardman BM; Nanda R; Jankowitz RC; Rimawi M; Abramson V; Pohlmann PR; Van Poznak C; Forero-Torres A; Liu MC; Rosenberg S; DeMeo MK; Burstein HJ; Winer EP; Krop IE; Partridge AH; Tolaney SM
    Breast Cancer Res Treat; 2021 Aug; 189(1):103-110. PubMed ID: 34120223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants.
    Oktay KH; Turan V; Bedoschi G; Abdo N; Bang H; Goldfarb S
    Cancer Med; 2023 Sep; 12(18):19225-19233. PubMed ID: 37698031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.
    Minisini AM; Menis J; Valent F; Andreetta C; Alessi B; Pascoletti G; Piga A; Fasola G; Puglisi F
    Anticancer Drugs; 2009 Jul; 20(6):503-7. PubMed ID: 19339872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.
    Kabirian R; Franzoi MA; Havas J; Coutant C; Tredan O; Levy C; Cottu P; Dhaini Mérimèche A; Guillermet S; Ferrero JM; Giacchetti S; Petit T; Dalenc F; Rouanet P; Everhard S; Martin AL; Pistilli B; Lambertini M; Vaz-Luis I; Di Meglio A
    JAMA Netw Open; 2023 Nov; 6(11):e2343910. PubMed ID: 37971739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
    Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer.
    Abusief ME; Missmer SA; Ginsburg ES; Weeks JC; Partridge AH
    Fertil Steril; 2012 Jan; 97(1):154-9. PubMed ID: 22192139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.